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ISSCR: Executive NoteGlobal Forum Discusses Stem Cell Research StrategyOn March 19, 2008, the ISSCR convened its inaugural Global
Forum in Half Moon Bay, California, bringing together the newly
established ISSCRGlobal Advisory Council with members of the
ISSCR leadership and experts in science, law, and public policy
(Table 1). The Global Advisory Council is the first external advi-
sory group of the ISSCR and is charged with helping the ISSCR
set a strategy to advance stem cell research and public educa-
tion in the face of a rapidly evolving scientific environment and
emergent clinical opportunities. The Global Advisory Council
consists of leaders in the public and private sectors who share
a deep commitment to the goals of the ISSCR. The Global Forum
set an ambitious 1 day agenda—to survey the state of stem cell
science, to evaluate the opportunities and challenges facing the
field, and to develop strategic direction for the ISSCR.
In exploring the current state of stem cell science, the Global
Forum applauded the recent breakthrough by several research
groups in developing human induced pluripotent stem (iPS) cells
(Lowry et al., 2008; Park et al., 2008; Takahashi et al., 2007; Yu
et al., 2007). While appreciating the speed at which the iPS cell
technology is progressing, several speakers noted major gaps
in our knowledge of the underlying mechanisms of reprogram-
ming, and emphasized the wealth of information and experience
still to be gained from embryonic stem cells and somatic cell
nuclear transfer that will be key to addressing these gaps. These
discussions highlighted the importance of educating funding and
regulatory bodies internationally about the scientific shortsight-
edness of pursuing one arm of research at the expense of
another. Indeed, a strong sentiment was expressed that medical
advancement demands that scientists be afforded the freedom,
opportunity, and encouragement to pursue a broad range of
scientific inquiry, from basic science to clinical translation, using
the most appropriate tools and methodologies.
A major topic of discussion at the Global Forum was the chal-
lenge of translating stem cell biology into clinical applications.
With the unprecedented pace of discovery has come an extraor-
dinary level of public expectation for the rapid clinical translation
of the research. Although stem cell research holds enormous
promise to address unmet clinical needs, Global Forum partici-
pants felt strongly that the ISSCR has a responsibility to educate
the public about the long and arduous process of clinical inves-
tigation. Stem cell science is already being sold at the clinical
level and marketed globally. Stem cell ‘‘tourism’’ and optimistic
promises of efficacy from poorly defined cell therapies threaten
not only the health and finances of individual patients, but the
reputation of the field. Hematopoietic stem cells have been
used in clinical bone marrow transplantation for many years
and have served as a key proof of principle for stem cell thera-
pies. However, outside of blood diseases, clinical uses of stem
cells remain at an early experimental stage. History has shown
that the path to new cures is long and fraught with unexpected
challenges. Communicating realistic expectation for both ad-
vances and setbacks in stem cell therapy, and identifying what
stem cells provide to the clinic at the levels of insight, diagnosis,
drug discovery, and therapy, will be essential to the long-term
success of the field.A Strong and Unified Voice for Stem Cell Research
More andmore, the stemcell field is perceived to hold fundamen-
tal healthcare implications for society, and the many advances in
the basic research of stem cells are receiving unprecedented
media coverage as well as regulatory scrutiny. The participants
in the Global Forum overwhelmingly recommended that the
ISSCR proactively develop a coordinated global public relations
strategy to provide sound information on the many exciting de-
velopments in the field, thereby leveraging the expertise of our
membership as the field advances toward controlled clinical tri-
als. The ISSCR is the major international professional organiza-
tion that represents the community of stem cell scientists, and
as such it is uniquely able to coordinate media contacts in scien-
tific communities worldwide. A working subgroup of the Global
Advisory Council is being formulated to coordinate this project,
which will necessitate a fund-raising effort to offset the costs of
such an enterprise. Providing an ongoing positive environment
for research relies on the effective communication of issues
suchas scientific advancesand their breadth of promise, national
and international policy initiatives, and advocating for global ac-
cess to advances in healthcare related to new stem cell-based
therapies. The consensus of the Global Forum attendees was
that building a strong voice on behalf of the stem cell community
would represent a wise investment.
Embracing Progress
The Global Forum presented an ideal opportunity for the ISSCR
to step back and assess its direction. Core strengths of the
ISSCR include its scientific integrity and excellence, and its out-
standingmembership comprised of research leaders worldwide.
Global Forum participants noted, however, that the field of stem
cell research is becoming progressively multidisciplinary and
dependent on a greater degree of international collaboration.
Recognizing that an ultimate goal is to harness the potential of
stem cells for use in drug discovery, diagnosis, and therapy,
Global Advisory Council members urged the ISSCR to develop
a strategy to engage a larger base of bioengineers and clinicians
to participate in the Society. The recommendations included
co-organizing a limited number of small workshops to bring
key leaders in these arenas together with ISSCR members to
explore common interests, and to promote further collaboration.
A precedent was set for regionally driven affiliated meetings in
2007 in Shanghai, and this mechanism could be extended to
multidisciplinary and clinical angles of stem cell biology such
as tissue engineering, imaging, cord blood banking, and dis-
ease-based themes. Weaving new technologies and clinical
topics into the current annual meeting series will also be an im-
portant step in maintaining relevance in a fast-moving research
environment.
The Global Forum was the first of what we hope will become
an annual ritual of introspection for the ISSCR. We are honored
to have such a distinguished advisory committee committed to
the same goals and vision of the ISSCR, and we feel confident
that the Global Advisory Council will be an invaluable asset to
our organization and the field in the years ahead.Cell Stem Cell 2, May 2008 ª2008 ISSCR 435
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Table 1. ISSCR Global Advisory Council
Name Title Affiliation
Mukesh Ambani Chairman Indian Petrochemicals Corporation Limited, Reliance Petroleum Limited, and
Reliance Retail Limited
Paul Berg, PhD Emeritus Professor Stanford University School of Medicine
Greg Bonfiglio, JD Managing Director Proteus Venture Partners
Brook H. Byers Partner Kleiner Perkins Caufield & Byers
Gerald Lokchung Chan Co-Founder Morningside Group
Gordon Keller, PhD Director McEwen Centre for Regenerative Medicine, University Health Network Senior
Scientist, Ontario Cancer Institute
Jim Yong Kim, MD, PhD Center Director Franc¸ois-Xavier Bagnoud Center for Health and Human Rights (FXB), Harvard
School of Public Health
Robert Klein Chair Independent Citizens’ Oversight Committee, California Institute for
Regenerative Medicine
William Kridel, PhD Principal and Founder Ferghana Partners Group
Rob McEwen Chairman and CEO US Gold Corporation
William Neaves, PhD President and Chief Executive
Officer
Stowers Institute for Medical Research
Beth Seidenberg, MD Partner Kleiner Perkins Caufield & Byers
Paul J. Simmons, PhD Professor and Director Centre for Stem Cell Research, Brown Foundation Institute of Molecular
Medicine (IMM), University of Texas Health Sciences Center at Houston
Eleni Tsakopoulos-
Kounalakis
President AKT Development
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